Eye health company Bausch + Lomb has secured regulatory approval from Health Canada for its enVista Envy full visual range intraocular lens (IOL).

Built on the enVista IOL platform, the new lens is designed to provide patients with a full range of vision and high tolerance to dysphotopsia, a common issue with glare and halos post-surgery.

A multicentre, randomised, and controlled clinical trial in Canada has shown promising long-term outcomes with the enVista Envy IOL.

Notably, 93% of patients experienced minimal dysphotopsia, and 94% had little to no difficulty with near vision while maintaining excellent distance vision without glasses, offering a continuous visual range of four dioptres.

The enVista Envy IOL incorporates ActivSync Optic Intelligent Energy Distribution and ClearPath technology, enhancing vision across various lighting conditions and reducing light scattering.

Additionally, the enVista Envy IOL’s Low-Cyl toric technology addresses both presbyopia and low levels of astigmatism, providing more precise correction with 0.5D steps or less throughout the cylinder range.

Bausch + Lomb global surgical president Luc Bonnefoy said: “enVista Envy is the next step in the dramatic transformation of our IOL portfolio.

“This first premium IOL on the enVista platform follows the US launch of enVista Aspire late last year. The company plans to launch complementary designs to round out the well-known enVista portfolio in the coming months to better address all patient needs.”

The enVista Envy IOLs aim to be commercially available in Canada next month.

Bausch + Lomb is also seeking regulatory approvals in other markets, including the US and Europe, for the enVista Envy IOL.

Last year, Bausch and Lomb and Heidelberg Engineering launched the new SeeLumafully digital surgical visualisation platform.